Idiopathic Pulmonary Fibrosis

The FDA has granted breakthrough therapy designation to pirfenidone for the treatment of adults with unclassifiable interstitial lung disease, according to a press release from Genentech.

In a recent survey of more than 2,000 U.S. adults, 86% reported not knowing the symptoms of pulmonary fibrosis, according to a press release from the Pulmonary Fibrosis Foundation.

As 2019 comes to a close, the Healio Pulmonology Editors have compiled a list of the most-read articles published this year.

Healio Pulmonology has you covered. As 2019 comes to a close, the Editors have compiled a list of updates in interstitial lung disease and idiopathic pulmonary fibrosis that Healio reported on this year.

Healio Pulmonology has compiled a list of articles highlighting the latest research and news on diagnosis and treatment for interstitial lung disease.

Although it missed its primary endpoint, the EXPAND trial has shown that use of a portable ex vivo lung perfusion system allowed successful transplantation of many lungs that were previously rejected by transplant centers.

New data demonstrating good agreement between transbronchial lung cryobiopsy and surgical lung biopsy support the use of the technology as an alternative to surgical biopsy for patients requiring lung tissue for a diagnosis of interstitial lung disease.

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in October.

Comparative serum protein biomarker profiling may allow researchers to identify patients with rheumatoid arthritis-associated interstitial lung disease and/or idiopathic pulmonary fibrosis, according to findings published in Arthritis Rheumatology.

Boehringer Ingelheim announced that the FDA has granted nintedanib breakthrough therapy designation for chronic fibrosing interstitial lung disease with a progressive phenotype, according to a press release.